With more biosimilar options available, we’ve seen a significant uptick in biosimilar market share. For example, Zarxio has captured more than 50% of market share in the Filgrastim market since ...

Visit us on Facebook. Opens in a new tab or window Visit us on X. Opens in a new tab or window Visit us on Instagram. Opens in a new tab or window Visit us on LinkedIn. Opens in a new tab or ...

Bahou, PharmD, MBA. Bahou detailed that his approach to integrating biosimilars into his organization revolves around addressing the escalating costs of drugs compared with patient premiums.

Of the patients in the study, 16.41% received originator products, 87.22% received biosimilars, 3.6% received both a biosimilar and an originator, and 6.2% were treated with both adalimumab and ...

Learn more about these drugs in Ten Things to Know About Biologics & Biosimilars. Made possible by the generous sponsors recognized below the graphic.

If you're thinking about beginning or switching to a new biologic or biosimilar, read the Questions to Ask Your Doctor About Biologics & Biosimilars. Made possible by the generous sponsors recognized ...

As of today, July 1st, Cyltezo (adalimumab-adbm) is commercially available in the U.S. It is the first and thus far only therapeutically interchangeable Humira-referenced biosimilar approved by ...

Reimbursement add-on The Medicare provision (PDF) in question consists of a temporary, five-year boost in Medicare Part B reimbursement rates for biosimilar products. The standard Part B ...

UnitedHealth said Amgen's (AMGN.O), opens new tab Amjevita will be among the biosimilars covered on its lists for commercial health plans, which are managed by its pharmacy benefits unit ...

The Bachelor of Science in Graphic Design at Drexel prepares students to inform, persuade, educate, and entertain through the creative use of words and images. The program prepares students with ...

Reuters Graphics Reuters Graphics Reuters Graphics ... In some cases, lower-cost generic or biosimilar versions of the original branded drugs are already available outside the U.S. Generic ...

The UK health service has well over a decade’s experience of dealing with biosimilars, but the NHS acknowledges that it has yet to make the most of these drugs. That was certainly one of the ...